Research Analysts’ Weekly Ratings Changes for Amgen (AMGN)

Several analysts have recently updated their ratings and price targets for Amgen (NASDAQ: AMGN):

• 2/7/2026 – Amgen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 2/6/2026 – Amgen had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Amgen had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a “neutral” rating on the stock.
• 2/5/2026 – Amgen had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a “hold” rating on the stock.
• 2/4/2026 – Amgen had its “buy” rating reaffirmed by analysts at TD Cowen.
• 2/4/2026 – Amgen had its price target raised by analysts at Citigroup Inc. from $315.00 to $345.00. They now have a “neutral” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a “neutral” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a “buy” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by analysts at Morgan Stanley from $304.00 to $309.00. They now have an “equal weight” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by analysts at Royal Bank Of Canada from $335.00 to $360.00. They now have an “outperform” rating on the stock.
• 2/4/2026 – Amgen had its price target raised by analysts at Leerink Partners from $305.00 to $355.00. They now have an “outperform” rating on the stock.
• 1/29/2026 – Amgen was given a new $400.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an “outperform” rating on the stock.
• 1/26/2026 – Amgen had its price target raised by analysts at UBS Group AG from $380.00 to $390.00. They now have a “buy” rating on the stock.
• 1/20/2026 – Amgen was downgraded by analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating. They now have a $335.00 price target on the stock.
• 1/8/2026 – Amgen had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an “outperform” rating on the stock.
• 1/8/2026 – Amgen had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a “buy” rating on the stock.
• 1/8/2026 – Amgen had its price target raised by analysts at Truist Financial Corporation from $318.00 to $319.00. They now have a “hold” rating on the stock.
• 1/7/2026 – Amgen was upgraded by analysts at UBS Group AG to a “strong-buy” rating.
• 1/6/2026 – Amgen is now covered by analysts at UBS Group AG. They set a “buy” rating and a $380.00 price target on the stock.
• 12/30/2025 – Amgen had its price target raised by analysts at Argus from $310.00 to $360.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Amgen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/12/2025 – Amgen had its price target lowered by analysts at Morgan Stanley from $329.00 to $304.00. They now have an “equal weight” rating on the stock.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s dividend payout ratio is currently 66.90%.

Insider Activity

In other news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.69% of the stock is currently owned by insiders.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.